

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM3/17 - Tumour Markers

Dead line: 08.08.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(180) CA 125					13							13	13	100%
Samples and groups	[kU/L]													
Sample A		121	22	18	13							13	13	100%
(4) LIA (CLIA, CMIA, ILMA); (1)	Abbott	133	18	13	7	0	CVPG	134	2,1	20%	107	161	7	
Other					6	0							6	
								2x 4/12, 1x 4/60, 1x 4/149, 2x 4/179						
Sample B		15,0	2,4	16	13							13	13	100%
(4) LIA (CLIA, CMIA, ILMA); (1)	Abbott	16,8	0,67	4,0	7	0	CVPG	17	0,25	20%	13,6	20,4	7	
Other					6	0							6	
								2x 4/12, 1x 4/60, 1x 4/149, 2x 4/179						
(181) CA 15-3					12							12	11	92%
Samples and groups	[kU/L]													
Sample A		19,4	2,5	13	12							12	11	92%
(4) LIA (CLIA, CMIA, ILMA); (1)	Abbott	19,4	1,6	8,0	7	0	CVPG	19,3	0,32	18%	15,8	22,8	7	
Other					5	0							5	
								1x 4/12, 1x 4/60, 1x 4/149, 2x 4/179						
Sample B		23,8	2,8	12	12							12	12	100%
(4) LIA (CLIA, CMIA, ILMA); (1)	Abbott	23,7	2,9	12	7	0	CVPG	23,6	0,51	18%	19,3	27,9	7	
Other					5	0							5	
								1x 4/12, 1x 4/60, 1x 4/149, 2x 4/179						
(182) CA 19-9					13							13	12	92%
Samples and groups	[kU/L]													
Sample A		5,67	0,87	15	13							13	12	92%
(4) LIA (CLIA, CMIA, ILMA); (1)	Abbott	5,27	0,47	8,9	6	0	CVPG	4,87	0,28	±2,8	2,07	7,67	6	
Other					7	0							7	
								3x 4/12, 1x 4/60, 1x 4/149, 2x 4/179						
Sample B		149	110	76	13							13	13	100%
(4) LIA (CLIA, CMIA, ILMA); (1)	Abbott	252	9,7	3,9	6	0	CVPG	250	5,2	20%	200	300	6	
Other					7	0							7	
								3x 4/12, 1x 4/60, 1x 4/149, 2x 4/179						
(183) CA 72-4					14							14	14	100%
Samples and groups	[kU/L]													
Sample A		9,50	0,61	6,4	14							14	14	100%
(4) LIA (CLIA, CMIA, ILMA); (60)	Roche	9,36	0,39	4,2	13	0	CVPG	9,38	0,11	20%	7,5	11,3	13	
Other					1	0							1	
								1x 1/185						
Sample B		3,98	0,24	6,1	14							14	14	100%
(4) LIA (CLIA, CMIA, ILMA); (60)	Roche	3,94	0,19	4,9	13	0	CVPG	3,93	0,045	20%	3,14	4,72	13	
Other					1	0							1	
								1x 1/185						
(184) CYFRA 21-1					12							12	12	100%
Samples and groups	[µg/L]													
Sample A		18,8	1,3	7,0	12							12	12	100%
(4) LIA (CLIA, CMIA, ILMA); (60)	Roche	18,8	1,3	7,1	8	0	CVPG	18,3	0,27	18%	15	21,6	8	
Other					4	0							4	
								4x 4/1						
Sample B		29,8	2,8	9,3	12							12	12	100%
(4) LIA (CLIA, CMIA, ILMA); (60)	Roche	30,3	4,2	14	8	0	CVPG	29,4	0,37	18%	24,1	34,7	8	
Other					4	0							4	
								4x 4/1						
(185) AFP					12							12	11	92%
Samples and groups	[µg/L]													
Sample A		7,15	0,60	8,4	12							12	12	100%
Other					12	0							12	
								4x 4/1, 3x 4/12, 3x 4/60, 1x 4/149, 1x 4/179						
Sample B		3,68	0,47	13	12							12	11	92%
Other					12	0							12	
								4x 4/1, 3x 4/12, 3x 4/60, 1x 4/149, 1x 4/179						
(186) hCG					13							13	13	100%
Samples and groups	[U/L]													
Sample A		16,5	2,0	12	13							13	13	100%

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM3/17 - Tumour Markers

Dead line: 08.08.2017

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(186) hCG					13							13	13	100%	
Samples and groups	[U/L]														
Sample A		16,5	2,0	12	13							13	13	100%	
Other					13	0						13			
							2x 4/1, 2x 4/12, 4x 4/60, 1x 4/149, 2x 4/179, 2x 4/210								
Sample B		9,99	1,4	14	13							13	13	100%	
Other					13	0						13			
							2x 4/1, 2x 4/12, 4x 4/60, 1x 4/149, 2x 4/179, 2x 4/210								
(189) CEA					13							13	11	85%	
Samples and groups	[µg/L]														
Sample A		1,93	0,19	9,7	13							13	11	85%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		2,03	0,082	4,0	6	0	CVPG	2,1	0,044	16%	1,76	2,44	6		
Other					7	0							7		
								3x 4/12, 1x 4/60, 1x 4/149, 2x 4/179							
Sample B		4,54	0,34	7,4	13							13	12	92%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		4,80	0,51	11	6	0	CVPG	4,78	0,077	16%	4,01	5,55	6		
Other					7	0							7		
								3x 4/12, 1x 4/60, 1x 4/149, 2x 4/179							
(190) TPS					4							2	2	100%	
Samples and groups	[U/L]														
Sample A		649	240	37	4							2	2	100%	
Other					4	0							2		
								1x 1/43, 1x 1/66, 2x 2/66							
Sample B		977	350	36	4							2	2	100%	
Other					4	0							2		
								1x 1/43, 1x 1/66, 2x 2/66							
(191) PSA					12							11	11	100%	
Samples and groups	[µg/L]														
Sample A		7,91	1,1	14	12							11	11	100%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		7,44	0,70	9,4	5	0	CVPG	7,22	0,15	15%	6,13	8,31	5		
Other					7	0							6		
								2x 4/12, 1x 4/60, 1x 4/149, 2x 4/179, 1x 4/195							
Sample B		0,116	0,042	37	12							11	11	100%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		0,085	0,004	5,2	5	0	CVPG	0,084	0,019 ±0,15		0 0,234		5		
Other					7	0							6		
								2x 4/12, 1x 4/60, 1x 4/149, 2x 4/179, 1x 4/195							
(194) NSE					11							11	11	100%	
Samples and groups	[µg/L]														
Sample A		47,4	3,4	7,2	11							11	11	100%	
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		47,8	3,3	7,0	10	0	CVPG	44,5	0,63	30%	31,1	57,9	10		
Other					1	0							1		
								1x 3/24							
Sample B		6,77	0,66	9,8	11							11	11	100%	
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		6,67	0,58	8,7	10	0	CVPG	5,95	0,12	30%	4,16	7,74	10		
Other					1	0							1		
								1x 3/24							
(195) SCCA					8							8	8	100%	
Samples and groups	[µg/L]														
Sample A		9,35	0,82	8,7	8							8	8	100%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		9,50	0,44	4,7	6	0	CVPG	9,84	0,26	23%	7,57	12,2	6		
Other					2	0							2		
								1x 3/24, 1x 4/60							
Sample B		2,15	0,67	31	8							8	8	100%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		2,44	0,24	9,7	6	0	CVPG	2,39	0,065 ±0,7		1,69	3,09	6		
Other					2	0							2		
								1x 3/24, 1x 4/60							
(198) free-PSA					10							10	9	90%	
Samples and groups	[µg/L]														
Sample A		6,27	0,29	4,7	10							10	9	90%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		6,20	0,12	1,9	5	0	CVPG	6,31	0,092	16%	5,3	7,32	5		
Other					5	0							5		
								2x 4/12, 1x 4/60, 1x 4/149, 1x 4/179							
Sample B		0,013	0,002	23	10							10	10	100%	
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		0,012	0,000	6,1	5	0	CVPG	0,011		±0,2	0 0,211		5		
Other					5	0							5		
								2x 4/12, 1x 4/60, 1x 4/149, 1x 4/179							

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM3/17 - Tumour Markers

Dead line: 08.08.2017

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability							
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(201) S-100					7							6	5	83%
Samples and groups	[µg/L]													
Sample A		0,095	0,022	23	7							6	5	83%
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		0,099	0,015	15	6	0	CVPG	0,093	0,023	32%	0,063	0,123	6	
Other					1	0						0		
													1x 2/98	
Sample B		0,033	0,005	18	7							6	6	100%
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		0,033	0,005	18	6	0	CVPG	0,031		0±0,013	0,018	0,044	6	
Other					1	0						0		
													1x 2/98	
(206) Calcitonin					3							2	2	100%
Samples and groups	[ng/L]													
Sample A		4,19	0,91	22	3							2	2	100%
Other					3	0						2		
													1x 1/24, 2x 4/29	
Sample B		21,9	2,0	9,3	3							2	2	100%
Other					3	0						2		
													1x 1/24, 2x 4/29	
(207) Thyreoglobulin					4							4	4	100%
Samples and groups	[µg/L]													
Sample A		119	54	45	4							4	4	100%
Other					4	0						4		
													1x 3/24, 2x 4/29, 1x 4/60	
Sample B		12,0	8,7	73	4							4	4	100%
Other					4	0						4		
													1x 3/24, 2x 4/29, 1x 4/60	
(208) beta-2-microglobulin					9							6	6	100%
Samples and groups	[mg/L]													
Sample A		1,50	0,13	8,4	9							6	6	100%
Other					9	0						6		
													1x 1/36, 1x 4/29, 1x 6/1, 1x 6/58, 1x 6/75, 1x 6/91, 3x 6/149	
Sample B		6,90	0,67	9,7	9							6	6	100%
Other					9	0						6		
													1x 1/36, 1x 4/29, 1x 6/1, 1x 6/58, 1x 6/75, 1x 6/91, 3x 6/149	

st_kn_p

End of report

Printed: 12.08.2017